Allergy Delabeling in Antibiotic Stewardship - Intervention
Optimizing Antibiotic Selection in Hematologic Malignancy Patients With Reported Beta-lactam Allergy - Intervention
Ebbing Lautenbach
3,800 participants
Apr 20, 2026
INTERVENTIONAL
Conditions
Summary
The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
Eligibility
Inclusion Criteria2
- all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service
- reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and/or carbapenem)
Exclusion Criteria6
- patients with a history of severe cutaneous adverse reaction
- patients with a history of Stevens-Johnson syndrome
- patients with a history of toxic epidermal necrolysis
- patients with a history of drug-induced exfoliative dermatitis
- patients with a history of drug reaction with eosinophilia and systemic symptoms
- patients with a history of acute generalized exanthematous pustulosis
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The RENEW-IN intervention includes a detailed assessment of the participant's beta-lactam allergy history and determination of a risk-level for allergy-delabeling.
Electronic medical record review for comparative analysis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07133074